NO955011L - Intracellulære bindingsproteiner og deres anvendelse - Google Patents

Intracellulære bindingsproteiner og deres anvendelse

Info

Publication number
NO955011L
NO955011L NO955011A NO955011A NO955011L NO 955011 L NO955011 L NO 955011L NO 955011 A NO955011 A NO 955011A NO 955011 A NO955011 A NO 955011A NO 955011 L NO955011 L NO 955011L
Authority
NO
Norway
Prior art keywords
pct
binding proteins
date dec
sec
nucleic acid
Prior art date
Application number
NO955011A
Other languages
English (en)
Other versions
NO319466B1 (no
NO955011D0 (no
Inventor
Fabien Schweighoffer
Bruno Tocque
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO955011L publication Critical patent/NO955011L/no
Publication of NO955011D0 publication Critical patent/NO955011D0/no
Publication of NO319466B1 publication Critical patent/NO319466B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072Regulatory proteins, e.g. tat, rev, vpt
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19955011A 1993-06-16 1995-12-11 Nukleinsyresekvens kodende intracellulaere bindingsproteiner og defekt, rekombinant virus, vektor, farmasoytisk preparat og anvendelse derav. NO319466B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9307241A FR2706486B1 (fr) 1993-06-16 1993-06-16 Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
PCT/FR1994/000714 WO1994029446A2 (fr) 1993-06-16 1994-06-15 Proteines intracellulaires de liaison (pil) et leurs utilisations

Publications (3)

Publication Number Publication Date
NO955011L true NO955011L (no) 1995-12-11
NO955011D0 NO955011D0 (no) 1995-12-11
NO319466B1 NO319466B1 (no) 2005-08-15

Family

ID=9448183

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19955011A NO319466B1 (no) 1993-06-16 1995-12-11 Nukleinsyresekvens kodende intracellulaere bindingsproteiner og defekt, rekombinant virus, vektor, farmasoytisk preparat og anvendelse derav.

Country Status (24)

Country Link
US (1) US6159947A (no)
EP (1) EP0703980B1 (no)
JP (1) JP4384260B2 (no)
KR (1) KR100342233B1 (no)
CN (1) CN1076052C (no)
AT (1) ATE231916T1 (no)
AU (1) AU7076394A (no)
BR (1) BR9407512A (no)
CA (1) CA2165458C (no)
CZ (1) CZ289039B6 (no)
DE (1) DE69432075T2 (no)
DK (1) DK0703980T3 (no)
ES (1) ES2191031T3 (no)
FI (1) FI120311B (no)
FR (1) FR2706486B1 (no)
HU (1) HU219138B (no)
NO (1) NO319466B1 (no)
NZ (1) NZ268038A (no)
PL (1) PL180760B1 (no)
RU (1) RU2218400C2 (no)
SK (1) SK285169B6 (no)
UA (1) UA46709C2 (no)
WO (1) WO1994029446A2 (no)
ZA (1) ZA944303B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790633B1 (en) * 1990-04-18 2004-09-14 Michael S. Brown Method of inhibiting a farnesyl transferase enzyme
US8003342B1 (en) 1990-04-18 2011-08-23 Board Of Regents, The University Of Texas System Method for identifying farnesyl transferase inhibitors
FR2724320B1 (fr) 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
US5518042A (en) * 1994-09-16 1996-05-21 Huyck Licensco, Inc. Papermaker's forming fabric with additional cross machine direction locator and fiber supporting yarns
FR2738151B1 (fr) * 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
CA2273823C (en) 1996-12-06 2007-06-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polypeptides encoded by a human lipase-like gene, compositions and methods
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
FR2758569B1 (fr) * 1997-01-20 1999-04-02 Centre Nat Rech Scient Materiel biologique pour le traitement d'un mammifere par transfert de gene d'anticorps et composition pharmaceutique le concernant
WO2000050089A2 (en) * 1999-02-26 2000-08-31 Mindset Biopharmaceuticals (Usa) Ltd. Regulation of the stability of recombinant proteins and antiboodies
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
DK1290023T3 (da) 2000-03-31 2011-02-14 Aventis Pharma Inc Nuklearfaktor KB inducerende faktor
AU2002338446A1 (en) * 2001-01-23 2002-11-05 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
US9328142B2 (en) 2011-05-25 2016-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of RAS oncoproteins
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
KR101602876B1 (ko) 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
BR122020006918B8 (pt) * 2014-10-23 2023-01-31 Singh Biotechnology Llc Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CA3025757A1 (en) 2016-05-27 2017-11-30 Orum Therapeutics Inc. Cytosol-penetrating antibody and use thereof
WO2019244086A1 (en) 2018-06-21 2019-12-26 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
CN110981943B (zh) * 2019-12-02 2021-08-03 清华大学 多肽及其在制备药物中的用途和药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3915952A1 (de) * 1989-05-12 1990-12-06 Peter Werner Wirkstoff/medikament/biotechnologisches verfahren zur behandlung von erkrankungen, die mit exo- oder endogenen intrazellulaeren proteinen (onkogene etc.) assoziert sind
AU8628291A (en) * 1990-09-25 1992-04-15 University Of Connecticut, The Prolonging expression of polynucleotides introduced into a cell
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
CA2120153C (en) * 1991-09-30 2006-06-06 Ira Pastan Recombinant immunotoxins
CA2125396A1 (en) * 1991-12-10 1993-06-24 Wayne A. Marasco Reactive neutralizing human anti-gp 120 recombinant antibody, dna coding the same and use thereof
CA2137558A1 (en) * 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules

Also Published As

Publication number Publication date
CA2165458A1 (fr) 1994-12-22
CA2165458C (fr) 2011-05-10
JPH08511162A (ja) 1996-11-26
KR100342233B1 (ko) 2002-12-05
CZ329595A3 (en) 1996-03-13
US6159947A (en) 2000-12-12
EP0703980A1 (fr) 1996-04-03
CN1076052C (zh) 2001-12-12
WO1994029446A3 (fr) 1995-02-02
DE69432075D1 (de) 2003-03-06
NZ268038A (en) 1997-12-19
HU219138B (hu) 2001-02-28
UA46709C2 (uk) 2002-06-17
NO319466B1 (no) 2005-08-15
ZA944303B (en) 1995-02-14
FI120311B (fi) 2009-09-15
PL312213A1 (en) 1996-04-01
ATE231916T1 (de) 2003-02-15
RU2218400C2 (ru) 2003-12-10
FR2706486A1 (fr) 1994-12-23
EP0703980B1 (fr) 2003-01-29
SK285169B6 (sk) 2006-07-07
WO1994029446A2 (fr) 1994-12-22
PL180760B1 (pl) 2001-04-30
FI956057A0 (fi) 1995-12-15
DK0703980T3 (da) 2003-05-19
HUT74266A (en) 1996-11-28
BR9407512A (pt) 1997-01-07
JP4384260B2 (ja) 2009-12-16
FR2706486B1 (fr) 1995-09-01
ES2191031T3 (es) 2003-09-01
CZ289039B6 (cs) 2001-10-17
NO955011D0 (no) 1995-12-11
AU7076394A (en) 1995-01-03
DE69432075T2 (de) 2003-09-04
CN1126491A (zh) 1996-07-10
HU9503615D0 (en) 1996-02-28
SK156895A3 (en) 1996-05-08
FI956057A (fi) 1995-12-15

Similar Documents

Publication Publication Date Title
NO955011L (no) Intracellulære bindingsproteiner og deres anvendelse
ATE400651T1 (de) Verwendung von grünem fluoreszenzprotein
FI934811A (fi) Stabiliserade enzymer och detergentfoereningar
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
ATE348175T1 (de) Method eder intrazellularen bindung von zielgerichteten molekülen
WO1996039429A3 (en) Serum protein produced exclusively in adipocytes
ATE239036T1 (de) Rekombinantes core-streptavidin
FI942442A (fi) Proteiinien tuotto 7B2-proteiinia käyttäen
DK0719328T3 (da) Genet GRB 3-3, varianter deraf og anvendelse deraf
NO972313L (no) Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav
ATE274351T1 (de) Verwendung von isolierten domänen des type-iv- kollagens zur änderung der zell- und gewebewechselwirkung
DK0773999T3 (da) OR-1, en orphan-receptor tilhørende kernereceptorfamilien
DK0788549T3 (da) Regulerende nukleinsyresekvenser og anvendelser
DK0778347T3 (da) Protein med formodede helicase- og ATPase-egenskaber, som binder ATP og nukleinsyre
WO2002074957A3 (en) Stress-responsive activator of p300 (strap) protein
ATE328088T1 (de) Transketolase-verwandtes protein

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees